Minded offers consumers online psychiatry focused on diagnosing and managing medication for anxiety, depression and insomnia through an online assessment and video visits with psychiatrists or nurse practitioners. Launched in 2021 in New York, it is available in New York, New Jersey, Pennsylvania, Florida, Texas, Illinois and California. Patients 18+ can sign up without prior diagnosis or insurance; a membership is $65 per month plus the cost of medication, which can be delivered or sent to a pharmacy. The company plans to expand nationwide to over 30 states, double the size of its medical team, and build technology to reduce administrative work for clinicians. Minded also intends to introduce DNA testing to improve precision and to offer psychedelics for treatment-resistant cases as those treatments prove safe and effective. Minded operates a telemedicine platform that lets patients who regularly take medication for anxiety, depression, and insomnia renew, adjust, and refill prescriptions online. Where appropriate, Minded can renew and adjust controlled medications and deliver medicines within 24 hours. The service is offered for an affordable price of $30 per month with no insurance required, and the company emphasizes continuous care and treatment adherence. Minded leverages proprietary technology to streamline clinician workflows and patient access, removing the need to travel to doctors' offices or pharmacies. The service is currently available in New York City and Nassau County, and the company has plans for rapid geographic expansion this year. Minded was founded by David Ronick (CEO), Gaspard de Dreuzy (Chairman), and Chris Dennis, MD, and has raised over $5M from outside investors.

Total raised

$30M

Funding rounds

3

Latest round

Seed

Latest activity

Feb 2022